CA2082169A1 - Freeze-dried preparation containing monoclonal antibody - Google Patents
Freeze-dried preparation containing monoclonal antibodyInfo
- Publication number
- CA2082169A1 CA2082169A1 CA002082169A CA2082169A CA2082169A1 CA 2082169 A1 CA2082169 A1 CA 2082169A1 CA 002082169 A CA002082169 A CA 002082169A CA 2082169 A CA2082169 A CA 2082169A CA 2082169 A1 CA2082169 A1 CA 2082169A1
- Authority
- CA
- Canada
- Prior art keywords
- freeze
- monoclonal antibody
- dried
- solution
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4343191 | 1991-03-08 | ||
JP3-43431 | 1991-03-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2082169A1 true CA2082169A1 (en) | 1992-09-09 |
Family
ID=12663510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002082169A Abandoned CA2082169A1 (en) | 1991-03-08 | 1992-02-28 | Freeze-dried preparation containing monoclonal antibody |
Country Status (10)
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
GB9122820D0 (en) * | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
JP2014148555A (ja) * | 1995-07-27 | 2014-08-21 | Genentech Inc | タンパク質の処方 |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
AU716785B2 (en) * | 1995-07-27 | 2000-03-09 | Genentech Inc. | Stabile isotonic lyophilized protein formulation |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
JP3624543B2 (ja) * | 1996-05-02 | 2005-03-02 | 東ソー株式会社 | 免疫反応試薬及びその製造方法 |
EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
AU2444899A (en) * | 1998-01-22 | 1999-08-09 | Astrazeneca Ab | Pharmaceutical formulation comprising an antibody and a citrate buffer |
US6750330B1 (en) * | 1998-05-14 | 2004-06-15 | Ashley Davis | Lyophilized tubulins |
WO2001047554A1 (fr) * | 1999-12-28 | 2001-07-05 | Chugai Seiyaku Kabushiki Kaisha | Compositions d'anticorps stables et preparations pour injection |
JP5490972B2 (ja) * | 2000-08-04 | 2014-05-14 | 中外製薬株式会社 | タンパク質注射製剤 |
SI1324776T2 (en) | 2000-10-12 | 2018-06-29 | Genentech, Inc. | Concentrated protein formulations with reduced viscosity |
US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
GB0113179D0 (en) * | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
MXPA04000747A (es) * | 2001-07-25 | 2004-07-08 | Protein Desing Labs Inc | Formulacion farmaceutica liofilizada estable de anticuerpos igg. |
US20040002451A1 (en) | 2002-06-20 | 2004-01-01 | Bruce Kerwin | Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
AU2004229335C1 (en) | 2003-04-04 | 2010-06-17 | Genentech, Inc. | High concentration antibody and protein formulations |
CA2532966C (en) | 2003-07-15 | 2012-12-04 | Chugai Seiyaku Kabushiki Kaisha | Igm production by transformed cells and methods for quantifying said igm production |
ATE518888T1 (de) | 2003-10-09 | 2011-08-15 | Chugai Pharmaceutical Co Ltd | Stabilisierte lösung mit hoher igm-konzentration |
EP1686137A4 (en) * | 2003-10-09 | 2009-10-28 | Chugai Pharmaceutical Co Ltd | PROCESS FOR STABILIZING PROTEIN SOLUTIONS |
US20070184050A1 (en) * | 2003-12-25 | 2007-08-09 | Kirin Beer Kabushiki Kaisha | Stable water-based medicinal preparation containing antibody |
JP5053264B2 (ja) * | 2005-05-19 | 2012-10-17 | アムジェン インコーポレイテッド | 抗体の安定性を増加させるための組成物および方法 |
KR20080031684A (ko) | 2005-06-14 | 2008-04-10 | 암젠 인코포레이티드 | 자가 - 완충성 단백질 제형 |
WO2007074880A1 (ja) * | 2005-12-28 | 2007-07-05 | Chugai Seiyaku Kabushiki Kaisha | 抗体含有安定化製剤 |
AR059066A1 (es) | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
TW200831129A (en) * | 2006-10-06 | 2008-08-01 | Amgen Inc | Stable formulations |
CL2007002881A1 (es) * | 2006-10-20 | 2008-05-09 | Amgen Inc | Formulacion estable que comprende un tampon con un ph de aproximadamente 4 y menos de 6, un cation divalente de 5-150 mm, un excipiente que comprende un azucar o un poliol, y un anticuerpo anti-receptor del factor de crecimiento epidermico; y metodo |
BRPI0809112A2 (pt) * | 2007-03-22 | 2014-08-26 | Imclone Llc | Formulações estáveis de anticorpos |
JP5322405B2 (ja) * | 2007-06-07 | 2013-10-23 | 小林製薬株式会社 | タンパク質含有組成物 |
SG174258A1 (en) | 2009-03-06 | 2011-10-28 | Genentech Inc | Antibody formulation |
BR112012022258A2 (pt) | 2010-03-01 | 2016-10-25 | Bayer Healthcare Llc | anticorpos monoclonais otimizados contra inibidor de trajetória de fator de tecido ( tfpi) |
WO2012028683A1 (en) | 2010-09-02 | 2012-03-08 | Novartis Ag | Antibody gel system for sustained drug delivery |
JP2014503482A (ja) | 2010-11-05 | 2014-02-13 | ノバルティス アーゲー | Il−17アンタゴニストを用いて関節リウマチを治療する方法 |
TWI606840B (zh) | 2010-11-11 | 2017-12-01 | 艾伯維生物技術有限責任公司 | 具有增進高濃度之抗-TNFα抗體之液體調配物 |
JP2012158615A (ja) * | 2012-05-28 | 2012-08-23 | Kobayashi Pharmaceutical Co Ltd | 還元糖によるタンパク質変性を抑制する方法 |
US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
US9937171B2 (en) | 2014-04-11 | 2018-04-10 | Acerta Pharma B.V. | Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase |
WO2015185998A2 (en) | 2014-04-11 | 2015-12-10 | Acerta Pharma B.V. | Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase |
WO2016024227A1 (en) | 2014-08-11 | 2016-02-18 | Acerta Pharma B.V. | Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment |
WO2016055982A1 (en) | 2014-10-10 | 2016-04-14 | Acerta Pharma B.V. | Quinoline and quinazoline compounds |
WO2016087994A1 (en) | 2014-12-05 | 2016-06-09 | Acerta Pharma B.V. | Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment |
ES2964640T3 (es) | 2015-08-13 | 2024-04-08 | Amgen Inc | Filtración en profundidad cargada de proteínas de unión al antígeno |
MA43162A (fr) | 2015-11-06 | 2018-09-12 | Acerta Pharma Bv | Inhibiteurs de type imidazopyrazine de tyrosine kinase de bruton |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2149304A (en) * | 1936-04-20 | 1939-03-07 | Sharp & Dohme Inc | Lyophilic biologically active substances |
SU700132A1 (ru) * | 1978-06-30 | 1979-11-30 | Томский Ордена Трудового Красного Знамени Научно-Исследовательский Институт Вакцин И Сывороток | Способ получени сухого препарата иммуноглобулина |
JPS57140724A (en) * | 1981-02-25 | 1982-08-31 | Green Cross Corp:The | Heat-treatment of aqueous solution containing cold insoluble globulin |
JPS58167518A (ja) * | 1982-03-29 | 1983-10-03 | Nippon Sekijiyuujishiya | ゼラチン誘導体添加静注用人免疫グロブリンの製造法 |
JPS6035263A (ja) * | 1983-08-05 | 1985-02-23 | Wako Pure Chem Ind Ltd | 不溶性担体に固定化された免疫活性物質の安定化法及び該物質を構成単位として含む生理活性物質測定用試薬 |
JPS60146833A (ja) * | 1984-01-10 | 1985-08-02 | Green Cross Corp:The | モノクロ−ナル抗体製剤 |
JP2565303B2 (ja) * | 1984-05-25 | 1996-12-18 | 三井東圧化学株式会社 | 緑膿菌感染症の予防治療剤 |
US4650772A (en) * | 1984-08-09 | 1987-03-17 | Abbott Laboratories | Monoclonal antibody stabilization |
JPH0669961B2 (ja) * | 1984-09-25 | 1994-09-07 | 株式会社ミドリ十字 | 免疫グロブリンの加熱処理方法 |
JPS61176532A (ja) * | 1985-01-30 | 1986-08-08 | Green Cross Corp:The | プラスミノ−ゲンアクチベ−タ−前駆体の安定化方法 |
JPH0825902B2 (ja) * | 1985-02-21 | 1996-03-13 | 株式会社ミドリ十字 | γ−グロブリンの加熱処理方法 |
JPH0825903B2 (ja) * | 1985-05-16 | 1996-03-13 | 株式会社ミドリ十字 | γ―グロブリン含有水溶液 |
JPS6178731A (ja) * | 1985-05-20 | 1986-04-22 | Green Cross Corp:The | 加熱処理免疫グロブリン製剤 |
DE3619565A1 (de) * | 1986-06-11 | 1987-12-17 | Behringwerke Ag | Verfahren zur herstellung einer pasteurisierten immunglobulinpraeparation |
JPS6388197A (ja) * | 1986-09-30 | 1988-04-19 | Tosoh Corp | モノクロナル抗体の安定化方法 |
AU591017B2 (en) * | 1986-12-15 | 1989-11-23 | Mitsui Toatsu Chemicals Inc. | Human monoclonal antibody and drug for prophylaxis and treatment of infectious diseases comprising same as effective ingredient |
ES2045027T3 (es) * | 1987-08-10 | 1994-01-16 | Miles Inc | Igm purificadas. |
JPH03504499A (ja) * | 1988-05-27 | 1991-10-03 | セントカー・インコーポレーテツド | 抗体試薬のための配合物 |
CA2049342A1 (en) * | 1989-03-27 | 1990-09-28 | Sally Bolmer | Formulations for stabilizing of igm antibodies |
JPH0384461A (ja) * | 1989-08-28 | 1991-04-10 | Green Cross Corp:The | 免疫学的凝集反応試薬及びその製法 |
JPH0911350A (ja) * | 1995-06-30 | 1997-01-14 | Olympus Optical Co Ltd | エネルギー硬化型樹脂を用いた光学素子の製造方法 |
-
1992
- 1992-02-27 JP JP4041015A patent/JPH0565233A/ja active Pending
- 1992-02-28 DE DE69225757T patent/DE69225757T2/de not_active Expired - Fee Related
- 1992-02-28 CA CA002082169A patent/CA2082169A1/en not_active Abandoned
- 1992-02-28 AU AU13375/92A patent/AU645187B2/en not_active Ceased
- 1992-02-28 DE DE69232617T patent/DE69232617T2/de not_active Expired - Fee Related
- 1992-02-28 EP EP97120255A patent/EP0841067B1/en not_active Revoked
- 1992-02-28 WO PCT/JP1992/000226 patent/WO1992015331A1/ja active IP Right Grant
- 1992-02-28 EP EP92906211A patent/EP0531539B1/en not_active Expired - Lifetime
- 1992-02-28 DK DK92906211T patent/DK0531539T3/da active
- 1992-02-28 DK DK97120255T patent/DK0841067T3/da active
- 1992-11-04 FI FI924982A patent/FI924982A0/fi not_active Application Discontinuation
- 1992-11-06 NO NO92924279A patent/NO924279L/no unknown
-
1994
- 1994-11-14 US US08/340,319 patent/US5908826A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP0531539B1 (en) | 1998-06-03 |
EP0841067A1 (en) | 1998-05-13 |
NO924279D0 (no) | 1992-11-06 |
US5908826A (en) | 1999-06-01 |
FI924982A (fi) | 1992-11-04 |
AU1337592A (en) | 1992-10-06 |
FI924982A0 (fi) | 1992-11-04 |
EP0531539A1 (en) | 1993-03-17 |
DE69225757D1 (de) | 1998-07-09 |
JPH0565233A (ja) | 1993-03-19 |
DK0531539T3 (da) | 1998-10-12 |
DE69225757T2 (de) | 1998-12-03 |
AU645187B2 (en) | 1994-01-06 |
EP0531539A4 (US20050032826A1-20050210-C00009.png) | 1995-04-05 |
NO924279L (no) | 1992-11-06 |
DE69232617T2 (de) | 2002-10-31 |
EP0841067B1 (en) | 2002-05-22 |
DE69232617D1 (de) | 2002-06-27 |
DK0841067T3 (da) | 2002-07-15 |
WO1992015331A1 (fr) | 1992-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2082169A1 (en) | Freeze-dried preparation containing monoclonal antibody | |
US6307028B1 (en) | Chromatographic method for high yield purification and viral inactivation of antibodies | |
US4318902A (en) | Concentrated immunoglobulin solution suited for intravenous administration | |
US5190752A (en) | Intravenously administerable polyclonal immunoglobulin preparation containing igm and method of manufacture | |
US4499073A (en) | Intravenously injectable immune serum globulin | |
US4396608A (en) | Intravenously injectable immune serum globulin | |
CA2292730C (en) | Stabilized antibody formulation | |
US4849508A (en) | Pasteurization of immunoglobulin solutions | |
US5410025A (en) | Unmodified intravenously administered immunoglobulin preparations containing immunoglobulin M and/or A | |
Barsumian et al. | Heterogeneity of group A streptococcal pyrogenic exotoxin type B | |
CA2226575A1 (en) | Stabile isotonic lyophilized protein formulation | |
US6955917B2 (en) | Chromatographic method for high yield purification and viral inactivation of antibodies | |
JPH02493A (ja) | 精製されたIgM | |
Lundblad et al. | The effect of processing methods on intravenous immune globulin preparations | |
Goodman et al. | Neutralization of bacteriophage by intact and degraded rabbit antibody | |
US5248767A (en) | Process for the preparation of a pasteurized immunoglobulin preparation using ethanol | |
JPS62283933A (ja) | 静注用非化学修飾免疫グロブリンの加熱処理方法 | |
VARASTEH et al. | Optimization of anti-Rh D immunoglobulin stability in the lyophilization processes | |
JPH0421647B2 (US20050032826A1-20050210-C00009.png) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |